Title of cohort

    3C study

    Acronym for cohort

    3C

    Name of Principal Investigator - Title

    Prof

    Name of Principal Investigator - First name

    Christophe

    Name of Principal Investigator - Last name

    Tzourio

    Address of institution -Institution

    INSERM - U1219

    Address of institution - Street address

    146 rue Léo-Saignat

    Address of institution - City

    Bordeaux Cedex

    Address of institution - Postcode

    33076

    Country

    France

    Website
    Contact email
    Funding source

    Inserm, CNRS, universités, MGEN, CNAM-TS, ISPED, DGS, GIS Institut de longévité, FDF, Conseils régionaux d'Aquitaine et de Bourgogne, Ministère chargé de la recherche, Agence

    Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

    Alzheimer's disease and other dementias

    Q1b. When are studies on the above condition(s) expected to become possible?

    Already possible

    Q2a. In a single sentence what is the stated aim of the cohort?

    Study the impact of vascular factors on dementia risk in the over 65 population.

    Q2b. What distinguishes this cohort from other population cohorts?

    Q3a. i) Number of publications that involve use of your cohort to date

    372

    Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)

    Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available

    http://www.three-city-study.com/publications.php

    Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population

    Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:

    65

    Q4a. Study criteria: what is the age range of participants at recruitment? To:

    until death

    Q4b. Study criteria: what are the inclusion criteria?

    65 or more years old subjects, inscribed on the electoral lists, and having a phone

    Q4c. Study criteria: what are the exclusion criteria?

    None

    Q5. What is the size of the cohort (i.e. how many participants have enrolled)?

    5,001-10,000 participants

    Q6a. Please describe what measures are used to characterise participants

    medical examination, psychometric tests

    Q6b. Are there additional measures for participants with a clinical disorder?

    Additional psychometric tests

    Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

    No

    If yes please specify

    Q7. What is the study design (select all that apply)?

    Prospective cohort|Longitudinal

    Q8. Are your cases matched by

    Q9a. Does your study include a specialised subset of control participants?

    No

    Q9b. If your study includes a specialised subset of control participants please describe

    Q10a. i) Please enter the data collection start date

    01/01/1999

    Q10a. ii) Please enter the data collection end date

    01/01/2016

    Q10a. iii) Is data collection for this study

    Data analysis ongoing

    Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?

    Yes - funding applied for/funding awarde

    Q11. Is data collected

    Through links to medical records

    Other please specify here

    CNAMTS, PMSI

    Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?

    No

    Q13a. Please give information on the format and availability of data stored in a database (1)

    Data summarised in database

    % available

    100

    Q13a. Please give information on the format and availability of data stored in a database (2)

    Database is web-based

    % available

    100

    Q13a. Please give information on the format and availability of data stored in a database (3)

    No

    % available

    Q13a. Please give information on the format and availability of data stored in a database (4)

    No

    % available

    Other (please specify)

    % available

    Q13b. Please give information on the format and availability of data held as individual records (1)

    Data is held as individual records

    % available

    100

    Q13b. Please give information on the format and availability of data held as individual records (2)

    No

    % available

    Q13b. Please give information on the format and availability of data held as individual records (3)

    No

    % available

    Q13b. Please give information on the format and availability of data held as individual records (4)

    No

    % available

    Please specify language used

    Q14a. Is data available to other groups?

    Yes

    Q14b. If data is available to other groups what is the access policy/mechanisms for access?

    Apply to PI or co-ordinator at resource| Access committee mechanism| Access committee mechanism| National access| International access| Access to industry

    Q15. What data sharing policy is specified as a condition of use?

    Data made publicly available after a specified time point

    Q16a. Are tissues/samples/DNA available to other groups?

    Yes

    Q16b i) If yes, please describe below:

    Living donors blood| Living donors: blood derivatives| Living donors: DNA

    Q16b. ii) In what form are tissues/samples/DNA supplied?

    Primary Samples: Stabilised samples (frozen or fixed)

    Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?

    Yes

    Q17. Is information on biological characteristics available to other groups?

    Yes, for all the cohort

    Number of Patients

    % of total cohort

Types: Population Cohorts
Member States: France
Diseases: Alzheimer's disease & other dementias
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF